keyword
https://read.qxmd.com/read/38447766/real-world-differences-in-dosing-and-clinical-utilization-of-onabotulinumtoxina-and-abobotulinumtoxina-in-the-treatment-of-upper-limb-spasticity
#1
JOURNAL ARTICLE
Zachary Bohart, Khashayar Dashtipour, Heakyung Kim, Marc Schwartz, Aleks Zuzek, Ritu Singh, Mariana Nelson
According to prescribing information, potency units are not interchangeable between botulinum toxin A products. This exploratory study compared real-world dosing and utilization of onabotulinumtoxinA and abobotulinumtoxinA in adults with upper limb spasticity. In this retrospective study, 101 clinicians provided chart data via online surveys for 215 US post-stroke patients treated for upper limb spasticity with ≥3 onabotulinumtoxinA or abobotulinumtoxinA doses (phase 1: 9/18/2020-12/10/2020; phase 2: 9/30/2021-12/7/2021)...
March 4, 2024: Toxicon: Official Journal of the International Society on Toxinology
https://read.qxmd.com/read/38319153/efficacy-and-safety-of-abobotulinumtoxina-for-treatment-of-moderate-to-severe-glabellar-lines-a-meta-analysis
#2
JOURNAL ARTICLE
Xiaopan Han, Jixian Bai, Jing Kuang
PURPOSE: This meta-analysis aimed to evaluate the safety and efficacy of abobotulinumtoxinA (ABO) and ABO solution for injection (ASI) for treating moderate-to-severe glabellar lines. METHODS: The EMBASE, PubMed, and web of science databases were systematically searched. Methodological quality was checked using the Cochrane Risk of Bias tool. We also performed statistical analyses using Stata software to examine the efficacy and safety of ABO. RESULTS: Nine randomized controlled trials were included in the meta-analysis...
February 2, 2024: Ophthalmic Plastic and Reconstructive Surgery
https://read.qxmd.com/read/38312815/long-term-follow-up-of-intravesical-abobotulinumtoxina-dysport%C3%A2-injections-in-women-with-idiopathic-detrusor-overactivity
#3
JOURNAL ARTICLE
Mohammad Sajjad Rahnama'i, Amin Bagheri, Elham Jahantabi, Hanieh Salehi-Pourmehr, Hadi Mostafaei, Brigitte Schurch, Aida Javan Balegh Marand, Sakineh Hajebrahimi
OBJECTIVE: Only a few numbers of studies have been published on the use of abobotulinumtoxinA (Dysport®) in idiopathic detrusor overactivity (IDO). This study reported the long-term follow-up of women with IDO who were treated with intravesical Dysport® injections. METHODS: Two hundred and thirty-six patients with IDO who had failed first-line conservative and antimuscarinic therapy received 500-900 units of Dysport® between April 2014 and July 2015...
January 2024: Asian Journal of Urology
https://read.qxmd.com/read/38300954/cost-effectiveness-of-abobotulinumtoxina-plus-best-supportive-care-compared-with-best-supportive-care-alone-for-early-treatment-of-adult-lower-limb-spasticity-following-an-acute-event
#4
JOURNAL ARTICLE
Peter Moore, Natalya Danchenko, Diana Weidlich, Alejandra Rodarte Tijerina
OBJECTIVES: Spasticity is an incurable chronic condition, and patients with spasticity frequently experience symptoms such as muscle stiffness, restricted mobility, fatigue, spasms, and pain. The study objective was to assess the cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for the early treatment of adult lower limb spasticity following an acute event (e.g. stroke or traumatic brain injury), from an Australian payer perspective...
2024: PloS One
https://read.qxmd.com/read/38206150/a-two-stage-injection-technique-and-dose-ranging-study-using-high-dose-abobotulinumtoxina-for-treating-platysmal-bands
#5
RANDOMIZED CONTROLLED TRIAL
John H Joseph, Allen Foulad, Victor B Hsue, Tahmineh Romero, Patrick Davis
BACKGROUND: AbobotulinumtoxinA (aboBoNT-A) is useful for the treatment of platysmal banding. This study evaluated the efficacy and safety of a standardized 2-staged injection technique using high doses of AboBoNT-A for treating platysmal banding. METHODS: This was a randomized, double-blinded, dose-ranging prospective study. Subjects included adults with moderate-to-severe platysmal bands (grade 3 or 4 on the validated 5-point photographic scale), who received either 120 U (Cohort 1) or 180 U (Cohort 2) of aboBoNT-A, followed by an optional 90 U touch-up...
January 1, 2024: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/38151057/mitigation-of-risk-of-botulinum-toxin-a-induced-blepharoptosis-with-hyperconcentrated-glabellar-injections
#6
JOURNAL ARTICLE
Soha Ghanian, Sarah P F Wambier, Carlos G Wambier
No abstract text is available yet for this article.
December 25, 2023: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/37806684/neuromodulators-for-skin
#7
REVIEW
Anya Costeloe, Angela Nguyen, Corey Maas
Neurotoxins are the most popular nonsurgical aesthetic procedure for men and women of all ages. Five botulinum toxin A (BoNTA) products represent the current palette of available BoNTA for cosmetic use. Off-label uses of BoNTA continue to expand and are now used for skin rejuvenation, to treat various skin disorders, and in facial nerve paralysis. Dermal and subdermal injections of dilute BoNTA has grown in popularity and been shown to improve skin texture and quality. Common targets for chemodenervation in facial nerve synkinesis are ipsilateral orbicularis oculi, mentalis, depressor anguli oris, buccinator, corrugator muscles, and the ipsilateral and/or contralateral frontalis...
November 2023: Facial Plastic Surgery Clinics of North America
https://read.qxmd.com/read/37794845/clinical-presentation-of-patients-with-lower-limb-spasticity-undergoing-routine-treatment-with-botulinum-toxin-baseline-findings-from-an-international-observational-study
#8
JOURNAL ARTICLE
Alberto Esquenazi, Richard D Zorowitz, Stephen Ashford, Pascal Maisonobe, Simon Page, Jorge Jacinto
OBJECTIVE: Describe how people with lower limb spasticity present for treatment in routine clinical practice. METHODS: Prospective, observational study (Clinicaltrials.gov: NCT04050527) of ambulatory adult patients (≥ 18 years) with unilateral lower limb spasticity (able to take ≥ 5 steps with or without assistance) presenting for routine spasticity management, including treatment with abobotulinumtoxinA. RESULTS: The study population included 430 adults with lower limb spasticity...
October 5, 2023: Journal of Rehabilitation Medicine
https://read.qxmd.com/read/37755987/a-cost-effectiveness-and-budget-impact-analysis-of-abobotulinumtoxina-in-greece
#9
JOURNAL ARTICLE
Nikolaos Nomikos, Christos Eleftheriou, Kostas Athanasakis
This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients' utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC...
September 8, 2023: Toxins
https://read.qxmd.com/read/37755958/a-uk-single-center-retrospective-noninterventional-study-of-clinical-outcomes-and-costs-of-two-botulinumtoxina-treatments-for-limb-spasticity
#10
JOURNAL ARTICLE
Clive Bezzina, Vadim Degtiar, Natalya Danchenko, Pascal Maisonobe, Benjamin Davis, Emanuel Engmann, Elodie Guyon, Sophie Lecanuet, John Whalen
Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015-2017) or aboBoNT-A (Cohort 2; 2017-2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs...
August 30, 2023: Toxins
https://read.qxmd.com/read/37574745/safety-of-botulinum-toxin-injections-in-children-less-than-one-year-old-a-retrospective-chart-review
#11
JOURNAL ARTICLE
Nikhil Deshpande, Mark E Gormley, Supreet Deshpande
PURPOSE: Infants can have muscle hypertonia due to cerebral palsy, muscle strength imbalances due to brachial plexus palsy, refractory clubfoot, and torticollis. These muscle problems can cause significant development impairments. A child with severe sialorrhea and dysphagia from leukodystrophy can aspirate, causing respiratory problems. Botulinum toxin (BoNT) injections can improve these conditions but may lead to adverse effects from the toxin spreading to non-targeted muscles, potentially impacting breathing, swallowing, and overall strength...
August 10, 2023: Journal of Pediatric Rehabilitation Medicine
https://read.qxmd.com/read/37557136/subjective-and-objective-measurements-of-the-facial-effects-of-microdoses-of-botulinum-toxin
#12
JOURNAL ARTICLE
Doris Hexsel, Indira Valente-Bezerra, Gabriela Mosena, Maria Antonia Oakim Mourao, Vitor Costa Fabris
INTRODUCTION: Studies have suggested that botulinum toxin A may improve skin quality, and application protocols using hyper-diluted doses of botulinum toxin (microdosing) have been studied as a way to achieve therapeutic goals without fully paralyzing the targeted muscles. OBJECTIVES: To evaluate the effects of a combined protocol utilizing both the standard dosing and the microdosing of AbobotulinumtoxinA for the improvement of skin quality, measured by objective and subjective measurements...
July 1, 2023: Dermatology Practical & Conceptual
https://read.qxmd.com/read/37517594/abobotulinumtoxina-improves-skin-properties-and-sebum-quality-in-the-rhino-mouse
#13
JOURNAL ARTICLE
Jacquie Maignel, Virginie Albinet, Maud Chusseau, Eric Lacoste
Besides neuronal cells, botulinum neurotoxins (BoNTs) can also affect other cell types such as fibroblasts or keratinocytes. These cells play a key role in skin conditions. Maintaining a high-quality sebum secretion is essential to avoid premature aging. This study explored the effect of abobotulinumtoxinA (aboBoNT-A) in the rhino mouse. Briefly, anaesthetized animals were injected via the intra-dermal route (ID; four sites of injection) by either vehicle or 0.1, 0.3 and 1 Unit aboBoNT-A per mouse. A reference group was administered with adapalene gel 0...
July 28, 2023: Toxicon: Official Journal of the International Society on Toxinology
https://read.qxmd.com/read/37507277/systematic-review-and-cost-effectiveness-analysis-of-the-treatment-of-post-stroke-spasticity-with-abobotulinumtoxina-compared-to-physiotherapy
#14
JOURNAL ARTICLE
María Errea Rodríguez, María Fernández, Juan Del Llano, Roberto Nuño-Solinís
OBJECTIVE: Post-stroke spasticity is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone...
2023: Farmacia Hospitalaria
https://read.qxmd.com/read/37490767/international-consensus-recommendations-on-the-aesthetic-usage-of-ready-to-use-abobotulinumtoxina-alluzience
#15
JOURNAL ARTICLE
Benjamin Ascher, Berthold-Josef Rzany, Philippe Kestemont, Alessio Redaelli, Benoit Hendrickx, Ivano Iozzo, Christoph Martschin, Alicia Milotich, Beatriz Molina, Hugues Cartier, Philippe Picaut, Inna Prygova
Alluzience (abobotulinumtoxinA RTU, Galderma; Lausanne, Switzerland) is the first ready to use (RTU) botulinum toxin-type A liquid solution approved for the treatment of glabellar lines in Europe. In this article, the authors provide consensus recommendations on the aesthetic usage of abobotulinumtoxinA RTU. Members of the International Board on Alluzience (IBA) convened to develop consensus on the treatment of glabellar lines as well as other facial wrinkles based on their own extensive experience. Consensus recommendations were developed to provide practical guidelines for injection of abobotulinumtoxinA RTU...
July 25, 2023: Aesthetic Surgery Journal
https://read.qxmd.com/read/37434519/effectiveness-of-ultrasound-guided-vs-electrical-stimulation-guided-botulinum-toxin-injections-in-triceps-surae-spasticity-after-stroke-a-randomized-controlled-study
#16
RANDOMIZED CONTROLLED TRIAL
Isabelle Hauret, Lech Dobija, Pascale Givron, Anna Goldstein, Bruno Pereira, Emmanuel Coudeyre
OBJECTIVE: To compare the efficacy of botulinum toxin injections using ultrasound-guidance vs electrical-stimulation-guidance in triceps surae (soleus and gastrocnemius) spasticity after stroke. DESIGN: A clinical, single-centre, prospective, interventional, single-blind, cross-over, randomized trial, with outpatients in the tertiary care hospital. After randomization, subjects received electrical-stimulation-guided, followed by ultrasound-guided abobotulinumtoxinA injection (n = 15), or the same 2 procedures in the reverse order (n = 15) with the same operator, 4 months apart...
July 11, 2023: Journal of Rehabilitation Medicine
https://read.qxmd.com/read/37414904/botulinum-toxin-utilization-treatment-patterns-and-healthcare-costs-among-patients-with-spasticity-or-cervical-dystonia-in-the-us
#17
JOURNAL ARTICLE
Michael Hull, Vamshi Ruthwik Anupindi, Mitchell DeKoven, Jing He, Jonathan Bouchard
INTRODUCTION: Spasticity and cervical dystonia (CD) are movement disorders with considerable direct and indirect healthcare cost implications. Although several studies have discussed their clinical impact, few have calculated the economic burden of these disorders. This study aimed to understand treatment/injection patterns of botulinum toxins type A (BoNT-As) and the characteristics, healthcare resource utilization (HCRU), and costs among patients with spasticity or CD. METHODS: Retrospective analyses were conducted using administrative healthcare claims from the IQVIA PharMetrics® Plus database, from October 1, 2015 to December 31, 2019...
July 7, 2023: Advances in Therapy
https://read.qxmd.com/read/37368683/safety-and-effectiveness-of-repeated-botulinum-toxin-a-intracavernosal-injections-in-men-with-erectile-dysfunction-unresponsive-to-approved-pharmacological-treatments-real-world-observational-data
#18
JOURNAL ARTICLE
François Giuliano, Pierre Denys, Charles Joussain
Intracavernosal injections of botulinum toxin A (BTX/A ic ) may be effective for difficult-to-treat erectile dysfunction (ED). This is a retrospective case series study of the effectiveness of repeated off-label BTX/A ic (onabotulinumtoxinA 100U, incobotulinumtoxinA 100U or abobotulinumtoxinA 500U) in men with ED and insufficient response to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandinE1 intracavernosal injections (PGE1 ICIs), defined as an International Index of Erectile Function-Erectile Function domain score (IIEF-EF) < 26 on treatment...
June 5, 2023: Toxins
https://read.qxmd.com/read/37335837/botulinum-toxins-and-zinc-from-theory-to-practice-a-systematic-review
#19
JOURNAL ARTICLE
Farid Mallat, Jerome Kaikati, Elio Kechichian
OBJECTIVE: The aims of this study were to determine whether zinc supplementation affects botulinum toxin's effect and longevity and to establish a transition from the molecular to the clinical aspect. METHODS: We conducted a systematic review in which we included all published studies on PubMed and Embase using the combination of the following terms: "zinc" AND (botox OR botulinum OR onabotulinumtoxinA OR abobotulinumtoxinA OR incobotulinumtoxinA). RESULTS: From the 260 yielded articles, 3 randomized control trials and 1 case report were retained...
June 20, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37316750/real-world-retrospective-multicenter-observational-study-on-the-use-of-the-first-liquid-abobotulinumtoxina-in-italy
#20
JOURNAL ARTICLE
Carlo Di Gregorio, Matteo Tretti-Clementoni, Magda Belmontesi, Marina Romagnoli, Alessandro Innocenti, Malvina Zanchi, Lucia Leone, Giovanni Damiani, Ivano Iozzo
INTRODUCTION: Randomized controlled trials (RCTs) suggested that liquid formulation of botulinum toxin type A (aboBoNT-A) is safe and effective, but data confirming these characteristics in a real-life heterogenous set of patients are currently lacking. This study aimed to assess the efficacy and safety of the ready-to-use aboBoNT-A solution in adults with moderate-to-severe glabellar wrinkles. METHODS: In this real-life, multicenter, retrospective, observational study, healthy adults were treated at baseline only with aboBoNT-A solution on the glabellar area and followed up for 24 weeks...
June 14, 2023: Dermatology and Therapy
keyword
keyword
9458
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.